Avalo Therapeutics Stock Performance
| AVTX Stock | USD 9.55 0.44 4.40% |
On a scale of 0 to 100, Avalo Therapeutics holds a performance score of 6. The firm shows a Beta (market volatility) of 0.35, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Avalo Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Avalo Therapeutics is expected to be smaller as well. Please check Avalo Therapeutics' total risk alpha, as well as the relationship between the kurtosis and market facilitation index , to make a quick decision on whether Avalo Therapeutics' price patterns will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Avalo Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Avalo Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
Five Day Return (4.50) | Year To Date Return 9.64 | Ten Year Return (99.95) | All Time Return (99.95) |
Last Split Factor 1:240 | Last Split Date 2023-12-29 |
1 | Where are the Opportunities in - Stock Traders Daily | 09/24/2024 |
2 | Acquisition by Truex Samantha of 24600 shares of Avalo Therapeutics at 9.88 subject to Rule 16b-3 | 11/01/2024 |
3 | Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates | 11/07/2024 |
4 | Avalo Therapeutics Receives 69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants | 11/12/2024 |
5 | Acquisition by Almenoff June Sherie of 500 shares of Avalo Therapeutics at 13.0 subject to Rule 16b-3 | 11/13/2024 |
6 | Avalo Therapeutics director June Almenoff acquires 12,749 in stock | 11/14/2024 |
7 | Acquisition by Neil Garry Arthur of 4000 shares of Avalo Therapeutics at 3.42 subject to Rule 16b-3 | 11/18/2024 |
8 | Avalo Therapeutics receives 69.4M in proceeds from full exercise of private placement warrants - MSN | 11/20/2024 |
| Begin Period Cash Flow | 13.3 M |
Avalo |
Avalo Therapeutics Relative Risk vs. Return Landscape
If you would invest 791.00 in Avalo Therapeutics on September 1, 2024 and sell it today you would earn a total of 164.00 from holding Avalo Therapeutics or generate 20.73% return on investment over 90 days. Avalo Therapeutics is currently generating 0.4347% in daily expected returns and assumes 5.2855% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Avalo, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Avalo Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Avalo Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Avalo Therapeutics, and traders can use it to determine the average amount a Avalo Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0822
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AVTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.29 actual daily | 47 53% of assets are more volatile |
Expected Return
| 0.43 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Avalo Therapeutics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Avalo Therapeutics by adding it to a well-diversified portfolio.
Avalo Therapeutics Fundamentals Growth
Avalo Stock prices reflect investors' perceptions of the future prospects and financial health of Avalo Therapeutics, and Avalo Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Avalo Stock performance.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (51.65) % | ||||
| Current Valuation | 18.62 M | ||||
| Shares Outstanding | 10.46 M | ||||
| Price To Book | 4.74 X | ||||
| Price To Sales | 121.86 X | ||||
| Revenue | 1.92 M | ||||
| Gross Profit | (7.94 M) | ||||
| EBITDA | (27.95 M) | ||||
| Net Income | (31.54 M) | ||||
| Cash And Equivalents | 11.25 M | ||||
| Cash Per Share | 1.20 X | ||||
| Total Debt | 537 K | ||||
| Debt To Equity | 5.62 % | ||||
| Current Ratio | 0.98 X | ||||
| Book Value Per Share | 2.18 X | ||||
| Cash Flow From Operations | (30.68 M) | ||||
| Earnings Per Share | 94.42 X | ||||
| Market Capitalization | 99.93 M | ||||
| Total Asset | 20.99 M | ||||
| Retained Earnings | (335.13 M) | ||||
| Working Capital | 3.78 M | ||||
About Avalo Therapeutics Performance
Evaluating Avalo Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Avalo Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Avalo Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.44 | 2.32 | |
| Return On Tangible Assets | (3.01) | (3.16) | |
| Return On Capital Employed | (1.43) | (1.50) | |
| Return On Assets | (1.50) | (1.58) | |
| Return On Equity | (4.32) | (4.53) |
Things to note about Avalo Therapeutics performance evaluation
Checking the ongoing alerts about Avalo Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Avalo Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Avalo Therapeutics had very high historical volatility over the last 90 days | |
| Avalo Therapeutics currently holds 537 K in liabilities with Debt to Equity (D/E) ratio of 5.62, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Avalo Therapeutics has a current ratio of 0.96, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Avalo Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 1.92 M. Net Loss for the year was (31.54 M) with loss before overhead, payroll, taxes, and interest of (7.94 M). | |
| Avalo Therapeutics currently holds about 11.25 M in cash with (30.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.2. | |
| Avalo Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 65.0% of Avalo Therapeutics shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Avalo Therapeutics receives 69.4M in proceeds from full exercise of private placement warrants - MSN |
- Analyzing Avalo Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Avalo Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Avalo Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Avalo Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Avalo Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Avalo Therapeutics' stock. These opinions can provide insight into Avalo Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.